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Background: Haploinsufficiency of SHANK3, due to either hemizygous gene deletion (termed 22q13 deletion
syndrome or Phelan-McDermid syndrome) or to gene mutation, accounts for about 0.5% of the cases of autism
spectrum disorder (ASD) and/or developmental delay, and there is evidence for a wider role for SHANK3 and
glutamate signaling abnormalities in ASD and related conditions. Therapeutic approaches that reverse deficits in
SHANK3-haploinsufficiency may therefore be broadly beneficial in ASD and in developmental delay.
Findings: We observed that daily intraperitoneal injections of human insulin-like growth factor 1 (IGF-1) over a
2-week period reversed deficits in hippocampal α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
signaling, long-term potentiation (LTP), and motor performance that we had previously reported in Shank3-deficient
mice. Positive effects were observed with an IGF-1 peptide derivative as well.
Conclusions: We observed significant beneficial effects of IGF-1 in a mouse model of ASD and of developmental
delay. Studies in mouse and human neuronal models of Rett syndrome also show benefits with IGF-1, raising the
possibility that this compound may have benefits broadly in ASD and related conditions, even with differing
molecular etiology. Given the extensive safety data for IGF-1 in children with short stature due to primary IGF-1
deficiency, IGF-1 is an attractive candidate for controlled clinical trials in SHANK3-deficiency and in ASD.
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SHANK proteins are master scaffolding proteins of the
postsynaptic density (PSD) of glutamatergic synapses
and are critical determinants of glutamate transmission
and synaptic spine dynamics [1]. Loss of one functional
copy of SHANK3 accounts for about 0.5% of the cases of
autism spectrum disorder (ASD) and/or developmental
delay [2], and there is likely a wider role for SHANK3
and glutamate signaling abnormalities in ASD and
related neurodevelopmental disorders [3,4]. Targeted
disruption of the full-length form of Shank3 (sometimes
called Shank3a) in mice leads to deficits in hippocampal* Correspondence: joseph.buxbaum@mssm.edu
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reproduction in any medium, provided the orAMPA signaling, long-term potentiation (LTP), and
motor performance [5-7], likely reflecting delayed synap-
tic development as shown by the reduced AMPA signal-
ing [5] and decreased levels of PSD-95 (unpublished
results). IGF-1, which enters the central nervous system
(CNS) through an interaction with lipoprotein-related
receptor 1 (LRP1) [8], has multiple effects on neuronal
and synaptic development and function, including effects
on neurogenesis and synaptogenesis [9]. IGF-1 treatment
also enhances the PSD as measured both by PSD length
and by levels of PSD-95 [10,11]. Recombinant human
IGF-1 has substantial human safety data and is approved
for use in children, making IGF-1 an attractive com-
pound for evaluation in neurodevelopmental disorders.
To investigate whether IGF-1 could reverse deficits in
a preclinical model of SHANK3-haploinsufficiency, we
made use of a mouse with hemizygous loss of full-length
Shank3 due to targeted disruption of the ankyrin repeatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cated in ASD, language delay, and intellectual disability
(ID), as there exist disruptive de novo point mutations in
ARD in patients with ASD and ID [12,13]. In all studies,
we compared heterozygous mice with wild-type litter-
mates using heterozygote × heterozygote mating. Con-
sistent with previous results from our group [5], LTP
induced by high-frequency stimulation was reduced in
the heterozygous mice compared to wild-type littermates
in the current experiments (Figures 1a and 2a) (forFigure 1 (1–3)IGF-1 reverses deficits in LTP and basal synaptic
properties in Shank3-deficient mice. Wild-type (WT) and
heterozygous (Het) mice were treated with saline or (1–3)IGF-1 for 2
weeks before testing (injections began at postnatal day (PND) 13 to 15
and animals were analyzed immediately after the last injection). Methods
for all experiments were as described previously [5], with 3 to 4 mice per
group, and 1 to 2 slices per animal. (a) Hippocampal LTP was induced
with high-frequency stimulation. Inset: Representative excitatory
postsynaptic potential traces at 90 min after LTP induction from
saline-injected (1) and (1–3)IGF-1-injected (2) heterozygous mice (scale
bar: 0.5 mV, 10 ms). (b) Input–output curves comparing field excitatory
postsynaptic potential (EPSP) slopes (mV/ms) as a function of stimulation
intensity (mA). EPSP: excitatory postsynaptic potential; Het: heterozygous;
LTP: long-term potentiation; PND: postnatal day; WT: wild-type.example, in Figure 2a, repeated measures ANOVA was
used for analysis of the last five time points, F(1,6) =
33.71, P = 0.001).
We first tested an active peptide derivative of IGF-1,
(1–3)IGF-1, which has been shown to cross the blood–
brain barrier and rescue Rett syndrome symptoms in
Mecp2-deficient mice [11]. We observed that intraperi-
toneal injections at 10 μg/g/day for 2 weeks restored
normal hippocampal LTP in Shank3 heterozygous mice
but had no effect on wild-type mice (repeated measures
ANOVA was used to analyze the last five time points,
F(3,11) = 6.07, P = 0.011). In post hoc analyses, vehicle-
treated heterozygous mice were significantly different from
wild-type mice (P = 0.004), while (1–3)IGF-1 treated het-
erozygous mice were not (P = 0.66). Furthermore, peptide
treatment reversed deficits in the mean slope of the input/
output (I/O) function (Figure 1b) (one-way ANOVA,
F(3,19) = 4.25, P = 0.02). Vehicle-treated heterozygous
mice were significantly different from vehicle-treated
wild-type mice (P = 0.001), while (1–3)IGF-1 treated
heterozygous mice were not different from vehicle-
treated wild-type (P = 0.89), and there were no signifi-
cant differences between vehicle-treated wild-type mice
and wild-type mice treated with IGF-1 (P = 0.812), so
further studies used just three conditions.
We next administered full-length IGF-1, like that used
in children with short stature due to primary IGF-1 defi-
ciency, by intraperitoneal injection at 240 μg/kg/day,
starting at PND 13 to 15 and continuing for 2 weeks
(Figure 2a). This dose, chosen because it represents the
maximum dose according to the current FDA label for
IGF-1, was effective in rescuing deficits in LTP (repeated
measures ANOVA was used to analyze the last five time
points, comparing heterozygous mice with and without
IGF-1, F(1,6)=28.04, P=0.002). In contrast, lower dose IGF-
1 (120 μg/kg/day for 2 weeks) was associated with more
modest reversal of deficits in LTP (for the last five time
points: F(1,6)=2.62, P=0.012), showing a dose–response
effect and providing preclinical dosing information.
Specific deficits in the glutamate AMPA receptor compo-
nent of neural signaling [5] were also reversed by a 2-week
treatment of 240 μg/kg/day full-length IGF-1 (Figure 2b).
The mean slope of the I/O function was 0.50 ± 0.14 for
wild-type, 0.34 ± 0.06 for Shank3 heterozygotes and 0.61 ±
0.059 for IGF-1 injected heterozygotes (one-way ANOVA,
F(2,9) = 8.62, P = 0.008). In post hoc analyses, vehicle-
treated heterozygous mice were significantly different
from vehicle-treated wild-type mice (P = 0.039), while
IGF-1-treated heterozygous mice were not different from
vehicle-treated wild-type mice (P = 0.12).
Patients with SHANK3-haploinsufficiency frequently
present with hypotonia and motor deficits of variable se-
verity, and we have observed subtle motor deficits in
Shank3-heterozygous mice [5,7]. After treating male
Figure 2 IGF-1 reverses deficits in LTP, AMPA signaling, and
motor function in Shank3-deficient mice. Wild-type (WT) and
heterozygous (Het) mice were treated with saline or recombinant
human IGF-1 (rhIGF-1) for 2 weeks (beginning at PND 13 to 15) before
testing and analyzed immediately after the last injection. Methods for all
experiments were as described previously [5,7], with 4 to 9 mice per
group. (a) Hippocampal LTP was induced with high-frequency
stimulation. Inset: Representative excitatory postsynaptic potential traces
at 90 min after LTP induction from saline-injected (1) and rhIGF-1
-injected (2) heterozygous mice (scale bar: 0.5 mV, 10 ms). (b) Slices
were incubated in the presence of the N-Methyl-D-aspartate (NMDA)
antagonist R-2-amino-5-phosphonopentanoate (APV) to expose AMPA
receptor signaling. (c) Mice were tested for motor performance and
motor learning by measuring latencies to fall off a rotating rod over
three trials. Het: heterozygous; LTP: long-term potentiation; NMDA: N-
Methyl-D-aspartate; rhIGF-1: recombinant human IGF-1; WT: wild-type.
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observed enhanced motor performance following treat-
ment (Figure 2c) (F(2,20) = 3.98, P = 0.03).
Our results provide preclinical evidence for a benefi-
cial role for IGF-1 in SHANK3-haploinsufficiency. More-
over, as there is emerging evidence that the SHANK3
pathway and the postsynaptic density, which it helps
sculpt, play a role in many neurodevelopmental disor-
ders, as evidenced by large-scale genetic, proteomic, and
gene expression studies [3,4,14], therapies for SHANK3
deficiency and synaptic development represent import-
ant targets that could have a widespread positive impact
for neurodevelopmental disorders. The beneficial effects
of IGF-1 in models of Rett syndrome [11,15] are consist-
ent with this hypothesis.
There are some limitations to the current study. We,
and others working with similar Shank3-deficient mice,
see only limited behavioral abnormalities, with none ex-
cept for rotarod deficits at the ages where we carried out
the IGF-1 treatments and electrophysiological studies.
For this reason, the phenotypes we measure are some-
what limited. In addition, a mechanistic understanding
of the neuronal effects of IGF-1 has eluded the neurosci-
ence community and we cannot precisely explain how
IGF-1 reverses the deficits observed. We do hope, how-
ever, that our findings, together with those on IGF-1 in
Rett syndrome models, may help spur further research
on the action of IGF-1 in the CNS. We did not see any
effect produced by the (1–3)IGF-1 peptide on control
animals but we did not test the effects of full-length
IGF-1 on wild-type mice. There could be enhanced LTP
or rotarod performance in control animals following
treatment with full-length IGF-1. Many drugs have ef-
fects on both healthy and non-healthy individuals and
there is hence no a priori reason to assume that IGF-1
has no effect on control animals. In fact, given the posi-
tive effects of IGF-1 in Rett syndrome models it is likely
that IGF-1 has a general effect on CNS function, which
might also be observed in controls.
In summary, our results show that IGF-1, approved
for use in children, can lead to functional improvements
in a mouse model of ASD and developmental delay,
representing an important preclinical step towards
novel therapeutics. Clinical trials of IGF-1 in SHANK3-
deficient individuals and in ASD are now underway
(ClinicalTrials.gov Identifier NCT01525901).Abbreviations
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